Alice P Chen, M.D.
National Cancer Institute (NCI)
18
18
14
N/A
0
11
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+35 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
You Lu, MD
West China Hospital
Shared therapeutic areas:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
AT13387 in Adults With Refractory Solid Tumors
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas
All 18 trials loaded